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ABSTRACT 
 
Background 
While radiotherapy (RT) is standard-of-care in elderly patients with malignant astrocytoma, 
the role of primary chemotherapy is poorly defined. The NOA-08 trial compared efficacy and 
safety of RT to temozolomide (TMZ) in patients with anaplastic astrocytoma (AA) or 
glioblastoma (GB).  
Methods 
Patients (N=412; 39 AA, 373 GB) > 65 years with a Karnofsky performance score > 60 were 
randomized in electronically generated blocks of variable length without stratification to 
receive standard RT to 60 Gy in 30 x 2 Gy fractions or TMZ in a one week on/one week off 
schedule. The primary endpoint was overall survival (OS). This trial (German Cancer Trials 
Registry ID 386 and NCT01502241) sought to demonstrate non-inferiority with a 25% margin 
of dose-dense TMZ compared with RT in the intention-to-treat population. The trial finished 
enrolment Nov 2 2009. Toxicity was graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE), version 3·0. 
Findings 
Patient characteristics in the intention-to-treat population [N=373 (178 patients RT, 195 
patients TMZ)] were balanced. Median OS [8·6 [7·3-10·2] months versus 9·6 [8·2-10·8] 
months; hazard ratio (HR)=1·09 (95% CI: 0·84-1·42)] of TMZ versus RT did not differ 
between both arms. Non-inferiority of TMZ compared with RT was significant (p=0·033). Also 
median event-free survival (EFS) [3·3 [3·2-4·1] months versus 4·7 [4·2-5·2] months did not 
differ with a HR=1·15 (0·92-1·43)] indicating non-inferiority (p=0·043). DNA repair protein O6-
methylguanine DNA-methyltransferase (MGMT) promoter methylation in tumor tissue 
(73/209 patients, 34·9%) tested was associated with prolonged OS [11·9 [9-not reached] 
versus 8·2 [7-10] months; HR=0·67 (0·38-1·29), p=0·0137]. Patients with MGMT promoter 
methylation had longer EFS when treated with TMZ (8·4 months [5·5-11·7] versus RT (4·6 
[4·2-5] months) whereas patients without MGMT promoter methylation had longer EFS when 
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treated with RT (4·6 [3·7-6·3] versus 3·3 [3-3·5] months). The most common intervention-
related adverse events in each group were leukocytopenia, lymphocytopenia and 
thrombocytopenia (grade 3/4 according to CTCAE: 12/4, 24/2, and 12/2 in the TMZ and 2, 1, 
and 4 in the RT arm), liver enzyme elevation (grade 3/4: 26/4 in the TMZ and 12/4 in the RT 
arm), infections (grade3/4: 26/9 in the TMZ and 15/8 in the RT arm), and thromboembolic 
events (grade 3/4: 18/6 in the TMZ and 1/4 in the RT arm).  
Interpretation 
NOA-08 demonstrates the non-inferiority of TMZ compared with RT in the treatment of 
elderly patients with malignant astrocytoma. To improve EFS, MGMT promoter methylation 
is a strong predictive biomarker for the choice between RT and TMZ.  
Funding 
Merck, Sharp & Dohme 
 
Keywords: glioma, radiotherapy, temozolomide, MGMT 
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INTRODUCTION 
 
Gliomas account for half of all intrinsic brain tumours and glioblastoma (GB) of World Health 
Organization (WHO) grade IV, the most malignant variant of glioma, accounts for half of all 
gliomas. On a population level, median survival with GB may still be below 6 months and 
age is the most important therapy-independent prognostic factor (www.cbtrus.org).1 In a few 
years more than half of the patients with GB will be older than 65 years of age and thus be 
classified as elderly.2 In the elderly, anaplastic astrocytoma (AA) (WHO grade III), a less 
common and malignant type of glioma with an overall better prognosis, shares molecular 
features and poor outcome with GB.3,4 
The current standard of care in elderly patients with GB or AA is resection or biopsy followed 
by involved-field radiotherapy (RT).5 The classical treatment schedule of RT consists of 60 
Gy in 30 fractions of 2 Gy although a hypofractionated schedule, e.g., 15 x 2·66 Gy7 is used 
in some centres. Concomitant and adjuvant radiochemotherapy with the alkylating agent 
temozolomide (TMZ) has become the standard of care in the younger population of GB 
patients.7 However, the benefit from TMZ is largely restricted to patients with tumours 
exhibiting promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) 
gene, which encodes a DNA repair protein associated with alkylator resistance.8,9 However, 
the benefit derived from the addition of chemotherapy decreases with age10 and age per se 
is considered a risk factor for cognitive side effects from cranial irradiation.2 Moreover, the 
tolerability of combined modality treatment of RT plus TMZ in the elderly appears to be 
reduced.11 Accordingly, TMZ chemotherapy alone has been explored and found to be 
feasible in GB of the elderly.12,13 Finally, we had reported encouraging progression-free 
survival rates at six months in patients with recurrent glioblastoma treated with a one week 
on one week off regimen.14 These promising studies encouraged the German 
Neurooncology Working Group (NOA) in 2005 to conduct a randomized phase III trial (NOA-
08) to demonstrate that dose-dense TMZ alone was not inferior to RT alone in the 
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management of newly diagnosed GB or AA in the elderly (> 65 years) and to evaluate the 
role of MGMT promoter methylation in this patient group. 
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PATIENTS AND METHODS 
 
 
Patients 
Patients with de novo histologically confirmed AA or GB and > 65 years of age, Karnofsky 
performance score (KPS) > 60, no prior systemic chemotherapy or RT to the brain, and 
adequate bone marrow reserve, liver, and renal function were eligible. Inclusion into the trial 
was based on local diagnosis. Histologic diagnoses were confirmed centrally at the Brain 
Tumour Reference Centre, German Society for Neuropathology and Neuroanatomy, in 
Düsseldorf at study entry, according to the WHO classifications 200015 and 200716. Failure to 
confirm AA or GB would have resulted in exclusion from the intention-to-treat-population 
(ITT). Of note, there was no change in the diagnostic criteria for AA or GB between the two 
versions of the WHO classification. 
 
Trial Design and Treatment 
NOA-08 (German Cancer Trials Registry ID 386 and NCT01502241) was approved by the 
ethics committees (EC) of all 23 participating sites. The study was conducted from May 15 
2005 through November 2 2010, with the last patient randomized on Nov 2 2009. The 
principal screening population consisted of patients who fulfilled the inclusion criteria 
histology, age and KPS. All study patients provided written informed consent. Patients were 
centrally randomized 1:1 to receive RT or TMZ in a one week on/one week off schedule (see 
Supplementary Information) (Fig. 1). At progression, treatment with TMZ in the RT arm and 
with RT in the TMZ arm was suggested in the protocol.   
If toxicity in the TMZ arm resulted in delays longer than 4 weeks prior to six months of 
treatment, TMZ was stopped and RT was performed. Treatment was stopped at disease 
progression or for unacceptable toxicity according to the Common Terminology Criteria for 
Adverse Events (CTCAE), version 3·0.  
 
Randomization and Masking 
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Sequence generation: Participant allocation was done according to an electronically 
generated randomization list in blocks of variable length without stratification. The sequence 
was generated prior to study start at the independent Contract Research Organization 
(CRO), alcedis (Gießen, Germany). 
Allocation concealment: Enrolment was done at the study site by an investigator. 
Assignment was initiated by FAX transmission from the study site to the CRO for single 
patients fulfilling the eligibility criteria. A responsible project manager at the CRO performed 
the randomization process and reported the assignment to the trial group via FAX 
transmission to the study site.    
Blinding and masking: Due to the procedures necessary for RT or TMZ treatment, blinding of 
investigators or participants was impossible. Similar the data had to be analysed with 
knowledge of the group assignment. Biases were prevented by strict adherence to an 
analysis plan that was written by the statistician (C.M) and approved by the lead 
investigators (W.W. and M.W.) prior to any analysis on the data.  
 
Evaluations  
Baseline examinations included physical examination, MRI, full blood cell counts, blood 
chemistry, Mini-Mental State Examination (MMSE), and quality-of-life questionnaire (QLQ) 
assessment with European Organisation for Research and Treatment of Cancer (EORTC) 
QLQ C-30 and BN-20. Patients received monthly clinical evaluation during therapies and a 
more comprehensive evaluation, which included MRI, MMSE, and QLQ 4 weeks after 
completing RT or 3 months after initiation of TMZ and every 3 months thereafter. In the RT 
arm full blood cell counts and blood chemistry were done at 4 weeks after starting RT. In the 
TMZ arm, full blood counts were done weekly and blood chemistry was done every 4 weeks 
during treatment. Toxicity was assessed biweekly. Tumour response or progression were 
defined according to Macdonald criteria17  (see Supplementary Information). Importantly, an 
apparent increase in tumor volume or contrast-enhancement in the radiation field in the first 
scan post RT was not deemed a progression but resulted in re-MRI 4-6 weeks later. 
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Molecular Methods  
The MGMT promoter methylation status (see Supplementary Methods) was determined by 
two distinct methylation-specific PCR (MSP) assays.18,19 Real-time PCR-based quantitative 
testing on 182 samples revealing 152 conclusive results was done at MDX Health.19  These 
same samples plus 70 samples from stereotactic biopsies with another 57 conclusive results 
were evaluated by conventional MSP at the German Brain Tumor Reference Center.18 
Where discrepancies were detected (in 4 samples; twice in each direction), the results from 
MDX Health were used.  
 
Statistical analysis 
The primary endpoint was overall survival (OS), measured in days from surgery to death. 
Secondary efficacy end points included EFS, best response, health-related quality of life 
(HRQOL) and safety. Event-free survival (EFS) was defined as time from surgery to first 
progression for patients with progression respectively to death for patients without 
progression. Patients without progression or death were censored at the day of the last 
contact. Univariate descriptive analysis of OS and EFS used Kaplan-Meier estimates20 and a 
Cox proportional hazard model for estimating Hazard Ratios (HR) with two-sided 95%-
confidence intervals (CI) and median OS and EFS with two-sided 95%-confidence intervals. 
The non-inferiority of TMZ compared to RT concerning OS and EFS was evaluated using a 
one-sided Log Rank test as described21,22 for a tolerance level of -25% difference 
(radiotherapy group – TMZ group) in median OS respectively EFS. Only OS was analyzed 
for confirmatory analysis and – regarding the non-inferiority hypotheses based on Hazard 
ratio, decided for a one-sided significance level of 0·05. 
The best responses17 in both arms were compared using Wilcoxon test. Multivariate 
analyses and HRQOL assessment23,24 is detailed in Supplementary Methods. All analyses of 
the primary and secondary efficacy endpoints were based on the intention-to-treat 
population, which included all randomized patients except patients who withdrew their 
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consent for data analysis or patients who did not receive any dose of trial medication after 
randomization. The per-protocol analysis of the primary endpoint included only patients 
without major protocol violations; these were unconfirmed histological confirmation of 
diagnosis (n=2) and age ≤ 65 years (n=9). The safety analyses concentrates on the 
documentation of adverse events (details in Supplementary Methods).  
The sample size of the trial was based on the primary endpoint and the non-inferiority 
hypothesis with an equivalence/non-inferiority limit of - 53 days or -25% of an assumed 
median OS of 7 months a one-sided significance level of 5%, a recruitment duration of 48 
months and a drop-out of 11%. 
Then, 412 subjects were found to be sufficient to achieve at least 80% power using the test 
procedure for testing the non-inferiority of TMZ for OS.21,22 Analyses were performed with 
Statistical Analysing Program SAS 9·1·3 (SAS Institute, Cary, NC). Alpha error was set to 
5% for all tests in this study. The data were documented during the study into the study 
documentation RDE system of Alcedis (Gießen, Germany). Alcedis monitored the data 
quality. 
 
This trial is registered as an International Standard Randomised Controlled Trial at the 
German Cancer Trials Registry (ID 386, quality level A) and with ClinicalTrials.gov 
(NCT01502241).  
 
Role of the funding sources 
The funding source, former Schering Plough, now Merck, Sharp & Dohme, had no role in the 
study design, collection, analysis, or interpretation of the data or in writing the study report or 
manuscript. Access to the raw data was limited to W.W., C.M., J.F., G.R. and M.W.  The 
corresponding author had full access to all of the data and the final responsibility to submit 
the publication. 
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RESULTS 
 
 
Patient characteristics 
The ITT population consisted of 373 elderly patients with centrally reviewed AA (11%) or GB 
(89%) who were randomized between May 15 2005 and November 2 2009 and received at 
least one dose of dose-dense TMZ or one fraction of RT. The per-protocol population 
consisted of 362 patients. The mean age of the ITT patients was 71 (RT arm) and 72 (TMZ 
arm) years, and risk factors were well balanced. Of note, there was a tendency to use 
steroids when RT was administered (Table 1). A total of 149 patients completed RT, and 126 
patients in the TMZ group completed at least 4 cycles (8 weeks) of chemotherapy. Patients 
in both arms had similar frequencies of salvage therapies (74 patients (70%) in the RT arm 
and 88 patients (62%) in the TMZ arm), which mainly consisted of TMZ in the RT arm and 
vice versa (Supplementary Table 1). The likelihood of receiving salvage therapy did not differ 
between patients with MGMT promoter methylated or unmethylated tumors (data not 
shown). 
 
Tolerability and toxicity 
In general, most patients tolerated both treatments well. There were no CTCAE grade 5 
toxicities in this study. CTCAE grade 2 - 4 toxicities were more frequent in the TMZ arm in all 
categories except for cutaneous AE (Table 2). The main reasons for discontinuation of RT 
were disease progression (n=10) and prolonged infection (n=8). The median number of TMZ 
cycles in arm B was 5 (range: 0-20). Discontinuations occurred due to progression (n=141) 
or toxicity (n=28).  
 
Clinical Efficacy 
At a minimal follow-up of 12 months (median 25·2 months [20.0-not reached (NR)]) after the 
last patients had been randomized, 228 deaths have been observed in the first year (RT: 
107, TMZ: 121). The estimation for the 1-year-OS rate was 37·4% (95%-CI: 30·2% – 44·7%) 
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in the RT arm with a median OS of 9·6 months [95%-CI: 8·2-10·8]. The TMZ group had an 
estimated 1-year OS of 34.4% (95%-CI: 27·6% - 41·4%) and a median survival of 8·6 
months [95%-CI: 7·3-10·2]. The non-inferiority of TMZ in comparison to RT for a tolerance 
level of 25% was statistically confirmed (Wellek test procedure, tolerance-level 25%: 
p=0·033)21,22 with a HR of 1·1 (95%-CI: 0·84 – 1·42) (Table 3 and Fig. 2a). The non-inferiority 
of TMZ was also confirmed in the analysis of the per-protocol population (Wellek test 
procedure, tolerance level 25%: p=0·028).  
Three-hundred-twenty-five patients experienced an event (progression or death) within in the 
first 12 months after surgery. There was no evidence for pseudoprogressions. The estimate 
for the 1-year-EFS rate was 9.3% (95%-CI: 5·5% – 14·3%) in the RT arm with a median EFS 
of 4·7 months [95%-CI: 4·2-5·2] and 156 events. The TMZ group had an estimated 1-year 
EFS of 12.0% (95%-CI: 7·8% - 17·1%) and a median EFS of 3·3 months [95%-CI: 3·2-4·1] 
and 169 events, which comprised toxicities and deaths without documented progression 
(Wellek test procedure, tolerance-level 25%: p=0·043)20, 21 with a HR of 1·15 (95%-CI: 0·92 – 
1·43) (Table 3 and Fig. 2b). The non-inferiority of TMZ for EFS was also confirmed in the 
analysis of the per-protocol population (Wellek test procedure, tolerance level 25%: 
p=0·041)21, 22.  
In the RT arm 106 patients experienced a progression. Seventy-four patients (69·8%) 
received salvage therapy, whereas 88 of 141 patients (62·4%) with progression received 
salvage therapy in the TMZ arm (p=0·227). There was a higher likelihood of second surgery 
in the TMZ arm [p=0·102; relative risk 1·6 (95% CI: 0·9 – 2·9)]. Otherwise, the patients in 
both arms had a similar frequency of salvage therapy, mainly TMZ in the RT arm, and vice 
versa (Supplementary Table 1). 
 
Prognostic and Predictive Factors 
MGMT promoter methylation was analysed for a subgroup of 209 patients (Table 1). This 
subgroup was comparable to the group of 165 patients without MGMT promoter methylation 
status concerning the distribution of type of primary surgery, histology, age and therapy 
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group. MGMT promoter methylation was detected in 73 of 209 evaluable patients (35%) 
(Table 1). This value was also detected in the subgroup of stereotactic biopsies with 20 of 59 
tested samples showing a MGMT promoter methylation (33·8%). The patients tested are 
representative for the ITT population in all relevant aspects and stereotactic biopsies 
resembled overall testing results (data not shown). Extent of resection (complete versus 
incomplete or biopsy; incomplete versus biopsy), and MGMT promoter methylation in tumor 
tissue, but not age in years neither as a continuous variable or dichotomized at age 70, or 
histology (AA versus GB) was found to be an independent prognostic factor for OS in the 
multivariate Cox analysis. An interaction was found between MGMT promoter methylation 
(methylated versus unmethylated) and therapy (Table 4a, Fig. 2c). These results were found 
also for EFS (Table 4b, Fig. 2d). 
Importantly, MGMT promoter methylation was associated with improved EFS only in the 
TMZ arm, but not in the RT arm (Fig. 2e,f, Table 4, Supplementary Table 2). In the TMZ arm, 
median EFS for patients with a methylated MGMT promoter was 8·5 months (95%-CI 5·6-
11·9 days) compared with 3 months (95%-CI 2·6-3·3 days) for patients with an unmethylated 
MGMT promoter (Fig. 2f and Supplementary Table 2b). In contrast, MGMT promoter 
methylation did not influence EFS in the RT arm. However, in patients with a methylated 
MGMT promoter EFS (and with a trend for OS) was worse with RT than with TMZ while in 
patients with an unmethylated MGMT promoter EFS (and with a trend for OS) was superior 
with RT than with TMZ (Fig. 2e,f and Supplementary Table 2b). 
 
Quality-of-Life Assessments 
HRQOL was comparable in both groups and available from 82% of all patients. No clinically 
meaningful or statistically remarkable difference between the two groups over time in any of 
the scales or cohorts were observed in any of the three cohorts, except more discomfort 
from communication deficits in the RT arm for patients who died between 6 and 12 months 
(p=0·002). Supplementary Figure 1 shows the trajectories of the HRQOL mean scores.  
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DISCUSSION 
NOA-08 broadens the spectrum of primary treatment of elderly patients with malignant 
gliomas by demonstrating the non-inferiority of primary treatment of elderly patients with 
malignant gliomas with TMZ alone. It implements MGMT promoter methylation as a relevant 
biomarker to decide, when patients may be undertreated with primary RT alone. 
The current standard of care for the increasing population of elderly patients with GB or AA 
is surgery or biopsy followed by RT.5 While RT alone is superior to best supportive care in 
elderly patients with GB and does not reduce QOL5, age per se may be a risk factor for 
cognitive side effects of cranial irradiation2, yet solid evidence for such cognitive side effects 
only exists for younger patients with irradiated low-grade tumors.25 Whether the addition of 
chemotherapy to RT7 improves outcome in the elderly, too, is currently explored. Many 
elderly patients do not even receive chemotherapy at recurrence.26 To challenge this current 
practice, new trial data are needed. In a recent ANOCEF trial, elderly patients > 70 years 
even with a low KPS < 70 seemed to benefit from TMZ alone when compared to historical 
controls.27 The NOA-08 trial for the first time demonstrates that dose-dense TMZ followed by 
RT as salvage is an alternative option in this patient population that is not inferior to RT 
alone followed by TMZ as salvage therapy. Given the limited life expectancy, dose-dense 
TMZ may be particularly suited for patients who may not have easy access to a radiation 
oncology facility and who prefer an oral medication administered and monitored close to 
home. However, a decline in cognitive functioning by RT should not be used for decision-
making since neither the NOA-08 data nor a previously published trial5 support a relevance 
of this presumed unwanted effect (Table 1 and Supplementary Fig. 1), although formal 
neurocognitive testing was not performed as a meaningful differentiation between the in part 
rapid disease progression (Table 3, supplementary Table 2b) and an evolving 
neurocognitive deficit was regarded impossible.   
More importantly, the major novelty reported here is the strong predictive power of the 
MGMT status for the benefit to be expected from either treatment modality for EFS and as a 
yet non-significant trend for OS: MGMT promoter methylated tumours respond better to TMZ 
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whereas unmethylated tumours respond better to RT (Fig. 2e,f, Table 4a,b). The data do not 
indicate that the non-significant effect for OS is due to resolving pseudoprogressions in the 
RT arm for methylated patients, but that these patients do better respond to the salvage 
TMZ treatment (Fig. 2e). The concept of pseudoprogression, although not the explicit 
terminology was well known at all study sites and regularly ruled out by short interval re-
scanning with MRI. Such stratification by a single biomarker has not been established in 
neurooncology despite supportive landmark data7,8 and is rare in general oncology, too. 
Accordingly, despite the acknowledged challenges associated with MGMT promoter 
methylation testing9, our data confirm the hypothesis generated by the recent cohort analysis 
of the German Glioma Network28, and in conjunction justify or even call for the routine testing 
of the MGMT promoter status in elderly patients with GB or AA, (i) to improve outcome, (ii) to 
prevent unnecessary toxicity and (iii) to save cost. 
 
NOA-08 has its limitations, not only because of the inherent weaknesses of a non-inferiority 
design, the selection of a generous tolerance level, a one-sided test procedure and possible 
non-proportional hazards for EFS. Only 56% of the tissues were available and informative 
for MGMT testing. The limited number of informative results is mainly due to the high 
percentage of stereotactic biopsies (Table 1), which may not qualify for MGMT testing due to 
the limited amount of tumour DNA that can be extracted from these small tissue specimens. 
Still, both the results from the testing of stereotactic biopsies resembled overall testing 
results and the patients tested are representative for the ITT population in all relevant 
aspects. While TMZ exhibited haematological toxicity, liver enzyme elevations, 
asthenia/fatigue and gastrointestinal side effects in a relevant number of patients, more 
severe grade 4 toxicity was rare (Table 2). This toxicity may well be due to the intensified 
dosing schedule used in this trial and particularly careful to evaluate in this elderly patient 
population, where also grade 2 toxicities may impact quality of life. In a recent trial in 
younger patients with GB, dose intensification in the adjuvant setting of primary combined 
modality treatment was not associated with increased OS, neither in patients with 
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methylated nor with unmethylated MGMT promoter status.29 Thus, it may well be that TMZ 
alone can be given in a conventional schedule in elderly patients with MGMT promoter 
methylated malignant glioma with comparable efficacy as demonstrated in this trial but 
reduced toxicity. However, at the time this trial was designed and conducted, there were no 
data that compared different TMZ schedules, but only data indicative of a superior efficacy of 
the dose-dense TMZ schedule14, which also led to the design of the glioblastoma trial 0525 
by the Radiation Therapy Oncology Group, which is reported to be negative.29 Similar, 
information on the potential non-inferiority of shorter courses of RT were only evolving, when 
NOA-08 already had been designed.6,30 
The age cut-off of 65 years to define elderly patients remains a controversial issue in 
neurooncology and even arbitrary in some patients.2 While it may shift towards 70 in the field 
of GB, it may shift to 60 in primary brain lymphoma where more aggressive treatments are 
explored. Other factors, such as neurological function or comorbidities are relevant, while in 
a generally well trial cohort such as the NOA-08 trial population, age alone is not prognostic 
any more (Table 4).  
We propose that future research efforts should explore the biological basis underlying the 
poorer outcome associated with gliomas in the elderly and should step-wise replace age per 
se as a basis for clinical decision making. In this regard, the identification of IDH1 mutations 
as a positive prognostic marker restricted to gliomas of younger patients was a first 
important step.4 AA in the elderly and primary GB both typically lack of IDH1 mutations and 
show a similar, unfavourable outcome3,4, justifying the inclusion of AA patients in this trial 
and the focus on MGMT but not IDH testing. In the limited number of non-GB patients 
included (Table 1), however, we find that AA patients do better with both treatments (HR 0·7, 
Table 4), albeit worse than younger patients with AA in previous trials.31,32 In that respect, 
the IDH-associated glioma-CpG island methylator phenotype-related profiles32 may dilute the 
predictive properties of MGMT promoter methylation demonstrated in the NOA-08 trial, thus 
providing a possible explanation why MGMT lacks predictive properties in anaplastic glioma 
in younger patients.31  
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In summary, NOA-08 demonstrated that TMZ chemotherapy alone is not inferior to RT alone 
in elderly patients with newly diagnosed GB or AA. This practice-changing observation will 
be confirmed in the independent Nordic trial that also reported a similar efficacy of RT alone 
and TMZ, albeit in a different regimen of 5 days TMZ out of 28 days, and in patients with GB 
aged 61 or more.30 More importantly, NOA-08 defines MGMT promoter methylation as a 
strong predictive biomarker that should help to guide clinicians to select among these two 
therapeutic options (Fig. 2 e,f and Supplementary Table 2). As a complementary approach 
and a next step of standardizing treatment of elderly patients with gliomas, the joint study of 
NCIC (CE·6) and EORTC (26062/22061) explores the efficacy of RT versus RT plus TMZ in 
elderly patients with GB. NOA-08 will certainly provoke a discussion on the standard-of-care 
arm, RT, in the methylated patients, especially since these patients do not shown a superior 
benefit from salvage TMZ compared to the unmethylated patients (Fig. 2e). Data from the 
NCIC/EORTC study may further validate the role of MGMT as a predictive biomarker in this 
patient population. It may confirm that TMZ produces no benefit in patients with 
unmethylated tumours, but, in case of a positive outcome, will provoke the question whether 
TMZ alone with deferred RT may be a sufficient treatment in patients with MGMT promoter 
methylated tumours. 
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FIGURE LEGENDS 
 
Figure 1. Trial design and CONSORT flow chart. Patients were randomized 1:1 to receive 
RT or TMZ chemotherapy in an one week on/ one week off schedule. Patient numbers 
represent the intention-to-treat population. At progression, patients treated initially with RT 
were commonly treated with TMZ. Patients who progressed on or after TMZ were often 
treated with RT (Abbreviations: intention-to-treat population, ITT; radiotherapy, RT; 
temozolomide, TMZ). 
 
Figure 2. Kaplan-Meier survival estimates. Data of OS (panel a) or EFS (panel b) were 
analyzed by treatment arm and tested for non-inferiority or by MGMT promoter methylation 
status (MGMT promoter methylated (MGMT+) or unmethylated (MGMT-), panels c and d) 
and tested for difference. Of note, Fig. 2b is presenting non-proportional curves, which are 
deemed unproblematic in the context of non-inferiority. Data of OS (panel e) or EFS (panel f) 
of the TMZ- or RT-treated patients were also analyzed by MGMT promoter methylation 
status (MGMT promoter methylated (MGMT+) or unmethylated (MGMT-) and tested for 
difference.  
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TABLES 
 
 
Table 1. Baseline Patient Characteristics  
 TMZ 
n = 195 
RT  
n = 178 
Median age (range), years 72 (66-84) 71 (66-82) 
Sex (female/male), n 107/88 90/88 
Central histopathology, n (%) 
AA 
GB 
Not confirmed 
 
17 (9) 
178 (91) 
0 
 
23 (13) 
153 (86) 
2 (1) 
Median KPS (range) [%] 
Prior to treatment 
After primary treatment* 
80 (60-100) 
70 (20-100) 
70 (0-100) 
80 (60-100) 
80 (50-100) 
70 (20-100) 
Median Mini-Mental State Examination score (out of 30)
(range) 
Prior to treatment 
After primary treatment* 
27 (9-30) 
 
28·5 (17-30) 
28 (0-30) 
27 (13-30) 
 
28 (12-30) 
27 (11-30) 
Resection, n 
Complete 
Partial 
Biopsy 
Missing 
 
53 
61 
80 
1 
 
51 
62 
65 
0 
Steroids, n 
None 
At the start of treatment only 
At the start and end of treatment* 
At the end of treatment only* 
No data 
 
97 
8 
27 
63 
0 
 
36 
26 
24 
90 
2 
 
Duration of treatment (range) [days] 77 (1-1137) 43 (1-65) 
Median time from surgery to start of study treatment (range)
[days] 
19 (4-47) 30.5 (11-76) 
MGMT promoter, n 
Methylated 
Unmethylated 
 Missing/inconclusive 
 
31 
77 
87 
 
42 
59 
77 
 
*Determined at first assessment post RT or the first 3 monthly assessment in the TMZ arm, 
which are both approximately 3 months after randomization. 
 
 
Table 2. Toxicity: Distinct events as recorded in the AE documentation. A new AE in 
the same category was counted here if the grade of the prior AE of the same kind had 
returned to CTCAE grade ≤ 1 
 TMZ 
n = 195 
RT  
n = 178 
CTCAE grade 2 3 4 2 3 4 
Haematological toxicity, n 
Neutropenia 
Lymphocytopenia 
Thrombocytopenia 
 
56 12 4 0 2 0 
60 44 2 4 1 0 
36 12 2 5 4 0 
Liver enzyme elevation, n 42 26 4 13 12 4 
Infection, n 54 26 9 40 15 8 
Thrombembolic event, n 16 18 6 10 4 4 
Asthenia / Fatigue, n 37 21 3 23 14 6 
Nausea / Vomiting, n 32 6 0 6 1 0 
Weight loss / Inappetence, n 8 2 0 2 0 0 
Neurologic symptoms 73 27 9 31 18 7 
Seizures 14 15 2 9 7 6 
Cutaneous AE (dermatitis, 
allergic rash, alopecia), n 
15 1 0 18 1 0 
 
 
 
 
Table 3. OS and EFS  
 TMZ 
n = 195 
(95%-CI) 
RT  
n = 178 
(95%-CI) 
Median EFS, HR  1·15 (0·92 – 1·43) 
Median EFS, months  3·3 (3·2 – 4·1) 4·7 (4·2 – 5·2)  
EFS rate at 6 months, %  30·1 (23·6 – 36·6) 35.1 (28·0 – 42·3) 
EFS rate at 12 months, %  12·0 (7·9 – 17·1) 9.3 (5·5 –14·2) 
Median OS, HR  1·09 (0·84 – 1·42) 
Median OS, months  8·6 (7·3 – 10·2) 9·6 (8·2 – 10·8) 
OS at 6 months, %  66·7 (60·0 – 73·4) 71·7 (65·0 – 78·4) 
OS at 12 months, %  34·4 (27·6 – 41·4) 37·4 (30·1 – 44·7) 
 Table 4a. Prognostic and predictive factors as determined in a multivariate Cox-
regression analysis for the primary endpoint OS (n=208 from 373)*. 
 Hazard ratio (95% CI) P value 
Age (years)  1·02 (0·98 – 1·06) 0·285 
Resection 
Complete versus incomplete versus biopsy  
 
1·84 (1·44 – 2·35) 
 
<0·0001 
AA versus GB  0·69 (0·38 – 1·22) 0·201 
TMZ, MGMT methylated  
 
RT, MGMT methylated and unmethylated  
 
TMZ, MGMT unmethylated (95%-CI) 
0·69 (0·35 – 1·16) 
 
1·0 (Reference) 
 
1·34 (0·92 – 1·95) 
0·139 
 
 
 
0·129 
 
 
 
Table 4b. Prognostic and predictive factors as determined in a multivariate Cox- 
regression analysis for EFS (n=208 from 373)*. 
 Hazard ratio (95% CI) P value 
Age (years)  1·01 (0·98 – 1·04) 0·674 
Resection  
Complete versus incomplete versus biopsy  
 
1·29 (1·07 – 1·56) 
 
0·008 
AA versus GB  0·75 (0·45 – 1·24) 0·255 
TMZ, MGMT methylated  
 
RT, methylated and unmethylated  
  
TMZ, MGMT unmethylated  
0·53 (0·33 -0·86) 
 
1·0 (Reference) 
 
1·95 (1·41 – 2·69) 
0·01 
 
 
 
 
0·01 
 
* 164 without methylation status, 1 without resection status 
 
